Loading clinical trials...
Loading clinical trials...
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Conditions
Interventions
Capecitabine
Vorinostat
Locations
14
United States
Tower Cancer Research Foundation
Beverly Hills, California, United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Contra Costa Regional Medical Center
Martinez, California, United States
Veterans Administration Hospital - Martinez
Martinez, California, United States
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Start Date
December 1, 2010
Primary Completion Date
June 1, 2015
Completion Date
October 1, 2016
Last Updated
April 14, 2017
NCT06980038
NCT06868433
NCT06636734
NCT04754321
NCT05063552
NCT04588038
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions